What Wegovy Was Originally Used For — and How Its Purpose Shifted

Why semaglutide started life as a diabetes treatment

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. GLP-1 is a hormone the gut releases naturally after eating; it nudges the pancreas to produce insulin, slows the rate at which the stomach empties, and signals to the brain that food has arrived. Researchers at Novo Nordisk saw these mechanisms as a promising target for blood-sugar control in type 2 diabetes, and semaglutide was developed with that goal in mind.

The diabetes product, sold as Ozempic, came first. It reached patients at doses of 0.5 mg and 1 mg weekly. Clinicians noticed something consistent in the trial data: people taking semaglutide were losing meaningful amounts of weight, more than could be explained by better blood-sugar control alone. That observation shifted the research agenda. The story of how semaglutide came to exist is, at its core, a story about researchers following the evidence wherever it led.

The full range of conditions semaglutide is now used for has expanded considerably since those early diabetes trials, but it's worth being precise about which product covers which indication, because the distinctions are clinically and legally meaningful.

The point where Wegovy became its own medicine

Novo Nordisk ran the STEP clinical programme specifically to test semaglutide at 2.4 mg weekly (roughly double the highest diabetes dose) in adults with obesity or overweight and a weight-related condition. The STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks, alongside lifestyle support. That was a different order of magnitude from what most existing treatments could offer.

On the strength of that evidence, regulators assessed Wegovy as a separate product with its own licence, its own dosing schedule and its own eligibility criteria. In the UK, the MHRA licensed Wegovy for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. NICE subsequently recommended it for NHS use within specialist weight management services, subject to conditions set out in NICE technology appraisal TA875.

The separation matters. Ozempic is still prescribed for type 2 diabetes and should not be used as a weight-loss medicine. Wegovy is the weight-management licence. They contain the same molecule at different doses, but they are not the same product in law or in practice. Understanding what Wegovy was originally designed to treat helps explain why the clinical criteria around it are drawn the way they are, and the clinical picture keeps developing.

How the medicine's role has continued to expand since its weight-loss licence

Honesty requires acknowledging that this is a fast-moving area, and it can feel hard to keep up. Since Wegovy's weight-management approval, semaglutide has accumulated further evidence and further licences. In January 2026 the MHRA approved a higher 7.2 mg weekly dose of Wegovy, and if you've ever wondered where the Wegovy name actually comes from, that background adds an interesting layer to how the brand has evolved alongside its expanding indications. Trials at 7.2 mg reported average weight losses approaching those seen with tirzepatide, which had previously led the field. You can find the full detail on the MHRA's announcement about the 7.2 mg pen.

In June 2026, the MHRA approved the first oral GLP-1 medicine licensed for weight loss in the UK: Wegovy tablets, a once-daily option for adults who prefer not to inject. And in July 2026, semaglutide received a further approval covering a specific form of liver disease. The original question (what was Wegovy used for) keeps acquiring new answers. A fuller overview of what Wegovy covers now brings that picture together.

For anyone considering weight management treatment, the landscape of available options has genuinely changed over the past few years, and what suits one person won't suit another. That's a clinical judgement, not a product comparison.

What this history means if you're deciding whether to explore treatment

The reason Wegovy's origins matter is not purely academic. A medicine that emerged from diabetes research, backed by decades of mechanistic understanding and large randomised trials, is a different proposition from a new compound with a thin evidence base. The weight-loss indication grew out of rigorous trial data, not a marketing pivot.

It also explains why these are prescription-only medicines requiring clinical assessment. The doses used for weight management are higher than those used in diabetes; the eligibility criteria exist for medical reasons; and a prescriber needs to review your full health picture before any treatment is started. That includes checking for conditions where semaglutide is not appropriate, discussing any medicines you already take, and deciding whether Wegovy or another option is the better fit. Cost is one factor people often think about early, what Wegovy costs through a private pharmacy is a reasonable thing to understand before you commit.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally, the same day it's submitted. If you'd like to know whether you might be clinically suitable, start your free consultation and a real clinician will assess your case.